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Abstract
Purpose Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for 
chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression 
prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-
type lung adenocarcinoma.
Methods After extensive literature review, a 5-member scientific committee generated 33 statements in 4 domains: gen-
eral aspects (n = 4); post-durvalumab in locally advanced disease (n = 6); post-first-line immunotherapy ± chemotherapy 
in advanced/metastatic disease (n = 11); and post-first-line platinum-based chemotherapy in advanced/metastatic disease 
(n = 12). A panel of 26 lung cancer experts completed 2 Delphi iterations through an online platform rating their degree of 
agreement/disagreement (first-round scale 1–5 and second-round scale 1–4, 1 = strongly disagree, 4/5 = strongly agree) for 
each statement. Second-round consensus: ≥ 70% of responses were in categories 1/2 (disagreement) or 3/4 (agreement).
Results Consensus was reached for 2/33 statements in the first Delphi round and in 29/31 statements in the second round. 
Important variables informing treatment at disease progression with an immunotherapy-based treatment include: disease 
aggressiveness, previous treatment, accumulated toxicity, progression-free interval, PD-L1 expression, and tumour muta-
tional burden. A platinum-based chemotherapy should follow a first-line immunotherapy treatment without chemotherapy. 
Treatment with docetaxel + nintedanib may be appropriate post-durvalumab in refractory patients or following progression 
to first-line chemotherapy + immunotherapy, or second-line chemotherapy after first-line immunotherapy, or first-line chemo-
therapy in some patients with low/negative PD-L1 expression, or second-line immunotherapy after first-line chemotherapy.
Conclusions To support decision making following progression to immunotherapy-based treatment in patients with advanced 
wild-type lung adenocarcinoma, a consensus document has been developed.
Keywords Delphi consensus · Treatment decisions · Lung adenocarcinoma · Immunotherapy · Chemotherapy · Nintedanib · 
Disease aggressiveness · Prior treatment · Accumulated toxicity · Progression-free interval · PD-L1 expression · Tumour 
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Introduction
The non-small cell lung cancer (NSCLC) treatment land-
scape has completely changed with the coming of age of 
immunotherapy. The past decade has seen great advances 
in the treatment of patients with advanced lung cancer, 
with the first clinically relevant improvements in overall 
survival (OS) occurring in the later lines of treatment fol-
lowed by significant advances in the first-line setting that 
have upended the treatment algorithm [1].
Upon progression to a platinum chemotherapy doublet, 
docetaxel or pemetrexed monotherapy was standard regi-
men for patients with advanced NSCLC. The addition of 
an anti-angiogenic agent (ramucirumab or nintedanib) to 
docetaxel increased OS in patients with lung adenocar-
cinoma who had progressed following first-line chemo-
therapy [2, 3]. The greatest survival improvement and 
reduction of tumour volume were reported in patients with 
particularly poor prognosis who rapidly progressed while 
receiving first-line chemotherapy and who had a larger 
tumour volume [4–6].
Also, in the post-chemotherapy setting, treatment with 
immunotherapy agents targeting PD-1/PD-L1 increased 
survival compared with docetaxel monotherapy, as sec-
ond-line treatment (nivolumab) [7, 8], and as second- and 
third-line treatments (pembrolizumab and atezolizumab) 
[9–12]. Higher PD-L1 tumour expression correlated with 
a better outcome to immunotherapy in patients with adeno-
carcinoma [7–10, 12]. Analyses requested by the European 
regulatory authorities for nivolumab reported a greater 
risk of early mortality when receiving nivolumab com-
pared with docetaxel in the group of patients with adeno-
carcinoma histology, rapid progression/refractoriness to a 
first-line chemotherapy, ECOG performance status (PS) 1, 
and low PD-L1 expression [13]. Similar analyses are not 
available for pembrolizumab or atezolizumab.
The greater effectiveness of immunotherapy condi-
tioned by PD-L1 expression and tumour mutational bur-
den (TMB) [14, 15] and the better outcomes in patients 
with rapid progression to first-line chemotherapy observed 
with anti-angiogenic agents in combination with docetaxel 
[2–4] appear to indicate that both therapeutic approaches 
could be complementary. Of note, there have been no ran-
domized clinical trials directly comparing single-agent 
immunotherapy with the combination of an anti-angio-
genic agent and docetaxel; cross-trial comparisons have 
been performed using the control arm of docetaxel mono-
therapy. This suggests that post-chemotherapy treatment 
and its subsequent therapeutic sequence require careful 
consideration.
On the other hand, several immunotherapy trials 
reported in 2017 and 2018 transformed the first-line 
treatment of metastatic NSCLC [1]. The preferred first-
line treatment option for patients without targetable muta-
tions is now an immunotherapy-based regimen alone or in 
combination with chemotherapy.
In patients with tumour PD-L1 expression ≥ 50%, the 
first-line recommendation is pembrolizumab alone, based 
on the KEYNOTE-024 Phase 3 study reporting a signifi-
cant improvement in OS with pembrolizumab compared 
with chemotherapy [after median follow-up of 25.2 months, 
median OS [mOS] of 30.0 months with pembrolizumab, 
and 14.2 months with chemotherapy, HR 0.63 (95% CI 
0.47–0.86)] [16, 17].
Pembrolizumab alone may also be an alternative for 
patients with PD-L1 expression of 1–49% who cannot 
receive chemotherapy, based on a significant improvement 
in OS with pembrolizumab compared with chemotherapy 
in the Phase 3 KEYNOTE-042 trial in patients with tumour 
PD-L1 expression of ≥ 1% [after median follow-up of 
14 months, mOS of 16.4 months vs. 12.1 months, HR 0.82 
(95% CI 0.71–0.93)] [18, 19]. However, this improvement 
in the overall population appeared to be driven by patients 
with PD-L1 expression ≥ 50% (mOS of 20.0 months vs. 
12.2 months [HR 0.70 (95% CI 0.58–0.86)]), representing 
47% of the overall population [18, 19].
The Phase 3 CheckMate 227 trial evaluating first-line ipil-
imumab (anti-CTLA-4) plus nivolumab vs. platinum-based 
chemotherapy met its co-primary endpoint of significantly 
prolonging PFS in patients with NSCLC with high TMB, 
defined as ≥ 10 mutations per megabase (mut/Mb) [15]. 
Median PFS (mPFS) in the immunotherapy combination 
arm was 7.2 months compared with 5.5 months (HR 0.58 
[97.5% CI 0.41–0.81]; p < 0.001). This PFS benefit in the 
high TMB population was observed irrespective of PD-L1 
expression. Preliminary results indicated a tendency toward 
improved OS in the high TMB population treated with the 
immunotherapy combination with a mOS of 23.0 months 
compared with 16.4 months in patients receiving chemo-
therapy [HR 0.79 (95% CI 0.56–1.10)] [20].
Four randomized studies in patients with non-squamous 
NSCLC showed that the addition of a PD-1/PD-L1 check-
point inhibitor to standard chemotherapy is superior to 
standard chemotherapy alone.
In patients without targetable mutations, first-line pem-
brolizumab in combination with platinum–pemetrexed was 
more effective than chemotherapy alone [21, 22]. In the 
Phase 3 KEYNOTE-189 trial of non-squamous NSCLC, 
OS improved in the pembrolizumab/chemotherapy arm com-
pared with the chemotherapy alone arm (with 18.7-month 
median follow-up, mOS was 22.0 months vs. 10.7 months 
[HR 0.56 (95% CI 0.45–0.70); p < 0.00001) [23]. The OS 
benefit obtained with pembrolizumab/chemotherapy was 
independent of PD-L1 expression and was also reported in 
patients with tumors with PD-L1 < 1% [HR 0.52 (95% CI 
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0.36–0.74)]. The co-primary endpoint of PFS also improved 
in the pembrolizumab arm.
Three Phase 3 studies of atezolizumab also showed sur-
vival improvement independently of PD-L1 expression. In 
IMpower150 in patients with non-squamous NSCLC, both 
OS and PFS improved in the four-drug combination arm of 
atezolizumab plus carboplatin paclitaxel and bevacizumab 
(ACPB) compared with a control chemotherapy arm with-
out atezolizumab; mOS of 19.2 months was reported in 
the atezolizumab arm compared with 14.7 months in the 
control arm (HR 0.78 [95% CI 0.64–0.96]; p = 0.02) [24]. 
IMpower130 evaluated atezolizumab plus carboplatin and 
nab-paclitaxel vs. a control chemotherapy arm without ate-
zolizumab. OS similarly improved in the atezolizumab arm, 
with a mOS of 18.6 months compared with 13.9 months in 
the control arm (HR 0.79 [95% CI 0.64–0.98]; p = 0.033) 
[25]. IMpower132 evaluated the combination of atezoli-
zumab plus carboplatin or cisplatin with pemetrexed vs. a 
control chemotherapy arm without atezolizumab in patients 
with advanced non-squamous NSCLC. PFS improved in the 
atezolizumab arm [mPFS 7.6 vs. 5.2 months (HR 0.6; 95% 
CI 0.49–0.72; p < 0.0001)], but the improvement in OS did 
not reach statistical significance [mOS 18.1 vs. 13.6 months 
(HR 0.81; 95% CI 0.64–1.03; p = 0.0797)], albeit not being 
fully mature [26].
Consolidation immunotherapy with durvalumab fol-
lowing chemoradiotherapy significantly improved the out-
come of patients with locally advanced, inoperable Stage 
III NSCLC in the Phase 3 PACIFIC study evaluating dur-
valumab vs. placebo [27, 28]. OS and PFS were both sig-
nificantly prolonged in the durvalumab arm compared with 
the placebo arm [OS HR 0.68 (99.73% CI 0.47–0.997); 
p = 0.0025 and mPFS 17.2 vs. 5.6 months, HR 0.51 (95% 
CI 0.41–0.63)].
These clinical trials changed the treatment algorithm of 
patients with advanced wild-type EGFR, ALK, ROS1, and 
BRAF lung adenocarcinoma. Immunotherapy-based regi-
mens are standard first-line treatments for advanced disease 
or for chemoradiotherapy consolidation in locally advanced 
disease. It is important to note that all clinical trials were 
performed using a control arm that is no longer consid-
ered a standard regimen and all second-line trials enrolled 
an immunotherapy-naïve patient population that no longer 
exists. Consequently, there is great uncertainty in the clinic 
as to how to best treat patients who progress after receiving 
immunotherapy. The new therapeutic scenario that results 
from great advances in the standard of care, although hav-
ing the potential to bring the best outcomes to patients for 
upfront treatment, does not address the best treatment to 
administer upon progressive disease. There is a need to opti-
mize the sequential treatment of currently available regimens 
to further improve the survival outcome of patients with 
advanced wild-type lung adenocarcinoma [1].
For issues that frequently occur in routine clinical prac-
tice, but for which there is not enough evidence, a systematic 
approach that aims to generate a consensus among experts 
can provide reliable guidance. The Delphi technique is com-
monly used to develop guidelines with health profession-
als [29]. The Delphi process allows panelists to reach an 
agreement by iteratively urging them to consider a series of 
problematic issues about key health decisions in conditions 
of low-grade evidence and is considered an appropriate tool 
to measure agreements and delineate therapeutic options for 




We aimed to develop a consensus document using the Delphi 
technique on treatment options in Spain beyond the first-
line setting for patients with advanced lung adenocarcinoma 
without targetable mutations (wild-type EGFR, ALK, ROS1, 
and BRAF). An external expert in Delphi methodology guar-
anteed the quality of the overall process.
Study design
Scientific committee
In April 2018, a scientific committee of five experts in com-
prehensive lung cancer management met to define and lead 
this consensus project. The following steps were carried out 
by the scientific committee: (1) selection of expert panel; (2) 
generation of clinical statements based on the extensive nar-
rative review of the current medical literature; (3) definition 
of the consensus levels and agreement on methodology; (4) 
interpretation of the results from the Delphi rounds; (5) final 
wording in the consensus document.
Expert panel
A panel of 26 medical oncologists specialized in lung cancer 
and renowned for their clinical and research experience were 
selected by the scientific committee. In this selection of an 




After an extensive narrative literature review, 33 statements 
belonging to 4 major domains were drafted by the scientific 
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committee. These domains covered general aspects and three 
clinical scenarios according to disease stages and treatment 
line:
1. General aspects of the current treatment of advanced 
wild-type lung adenocarcinoma (four statements)
2. Durvalumab as consolidation therapy after platinum-
based chemoradiotherapy: impact on subsequent treat-
ment lines (six statements)
3. First-line immunotherapy ± chemotherapy: impact on 
optimal treatment sequencing in second- and further 
treatment lines (11 statements)
4. Treatment after platinum-based chemotherapy with-
out immunotherapy: options and optimal therapeutic 
sequencing (12 statements)
It was established that these statements would be evalu-
ated in patients with wild-type lung adenocarcinoma with a 
good general condition (ECOG PS 0–1) without contrain-
dications to any type of treatment. Non-immunotherapy 
treatment regimens included in the statements were limited 
to those approved and reimbursed by the Spanish National 
Health System. These prerequisites were included to sim-
plify the interpretation and allow for a better clinical appli-
cability of any consensus.
Consensus levels
The expert panel completed two Delphi rounds of the state-
ments through an online platform. In the first round, the 26 
panelists voted using the following answers: (1) “strongly 
disagree”; (2) “basically disagree”; (3) “doubtful”; (4) “basi-
cally agree”; and (5) “strongly agree”. A consensus existed 
if ≥ 70% of the responses were classified as “strongly agree” 
or “strongly disagree”. If the consensus was 100%, it was 
considered “unanimous”. All statements reaching consensus 
in the first round did not undergo the second Delphi round. 
The statements that had ≥ 15% of “doubtful” responses were 
reassessed by the scientific committee, to discern if this was 
due to the ambiguity of the statement itself, in which case it 
was reformulated, or due to the issue being controversial in 
itself, in which case the statement remained unchanged in 
the second Delphi round.
A second Delphi round was held for all statements with-
out consensus in the first round. In this second round, the fol-
lowing answers were available: (1) “strongly disagree”; (2) 
“basically disagree”; (3) “basically agree”; and (4) “strongly 
agree”. The reduction to four answers in this second round is 
contemplated in the Delphi methodology to prompt experts 
to decide in favour or against a statement and avoids the 
tendency to give a neutral answer. A consensus was defined 
if ≥ 70% of the responses were in categories 1 and 2 (consen-
sus in the disagreement) or in categories 3 and 4 (consensus 
in the agreement), and the consensus was considered unani-
mous if 100% was reached in either of the two categories. A 
majority was defined when the percentage of agreement or 
disagreement was ≥ 60% but < 70%. A dissent was defined 
as < 60% agreement.
All 26 panelists responded to both Delphi rounds. The 
first round took place from 11 July 2018 to 21 August 2018 
and the second round took place from 7 September 2018 
to 17 October 2018. This study consisted of a survey of 
expert opinions and no patient data were collected, so no 
specific independent ethical or research review or approval 
was necessary.
Statistical analysis
Categorical and ordinal variables were summarized with 
counts and percentages tabulated by round. The SPSS v25 
(IBM) program package was used for the statistical analyses.
Development of the consensus manuscript
All five members of the scientific committee wrote the con-
sensus manuscript, which was then enriched with feedback 
from three external experts (Enriqueta Felip, Pilar Garrido, 
and Luís Paz-Ares).
This project began in April 2018 and ended in March 
2019. During this time and when this article was drafted, 
newly published literature and congress presentations were 
reviewed to analyze the clinical implications of any new data 
in patients with advanced NSCLC and to provide support for 
the consensus statements.
Results
In the first Delphi round, 33 statements were evaluated, and 
a consensus was reached for 2 statements (6%). In the sec-
ond Delphi round, the remaining 31 statements were evalu-
ated, including 1 statement that had been reformulated: in 7 
statements, there was unanimity in the agreement and in 22 
statements, there was consensus in the agreement (overall 
consensus: 94%). For one statement, there was majority in 
disagreement and in one statement, there was dissent.
General aspects of the current treatment 
of advanced wild‑type lung adenocarcinoma
Table 1 shows the responses for the four statements in this 
domain. There was a high degree of consensus (92–100%) 
on the fact that the incorporation of new highly effective 
immunotherapy-based treatments as first-line treatment 
of advanced wild-type lung adenocarcinoma has gener-
ated uncertainty regarding optimal treatment upon disease 
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progression. It is not possible to generate high-level sci-
entific evidence because the second-line Phase 3 studies 
leading to regulatory approvals will not be repeated with 
patient populations that have received the current standard 
of first-line immunotherapy. In this case, expert opinion and 
clinical experience are necessary to define what is the best 
therapeutic sequence to offer patients who have reported 
disease progression.
Durvalumab as consolidation therapy 
after platinum‑based chemoradiotherapy in Stage 
III wild‑type lung adenocarcinoma: impact 
on subsequent treatment lines
Table 2 shows the responses for the six statements in this 
domain. There was high agreement (85–96%) that the fol-
lowing variables may define the optimal regimens to be 
administered upon progression to durvalumab in the locally 
advanced setting: progression-free interval, clinical aggres-
siveness of the progression (early progression and high 
symptomatic tumour load), accumulated toxicity from pre-
vious treatments, tumour PD-L1 expression, and TMB.
Patients treated with platinum-based chemoradiotherapy 
progressing during durvalumab consolidation, can be classi-
fied as refractory to platinum when the interval from the end 
of chemoradiotherapy to progression is less than 6 months. 
For this reason, the combination of docetaxel and nintedanib 
could be an appropriate therapeutic option. If this disease-
free interval is longer than 12 months, during treatment with 
durvalumab or when it has already ended, a platinum-based 
chemotherapy would be an appropriate therapeutic option. If 
the interval is between 6 and 12 months, the decision could 
be based on the proximity to 6 vs. 12 months, the clinical 
aggressiveness of the progression (high symptomatic tumour 
burden) and reports of previously accumulated toxicity.
There is not much evidence that rechallenging patients 
with immunotherapy-based treatment is effective 
[30–32]. Moreover, there is no evidence for rechallenging 
patients after chemoradiotherapy consolidation with dur-
valumab, so patients should be encouraged to participate in 
clinical trials. In any case, an immunotherapy rechallenge 
might be justified with a longer interval between the end 
of durvalumab and the progression of the disease and with 
higher tumour PD-L1 expression and high TMB.
First‑line immunotherapy ± chemotherapy 
in advanced wild‑type lung adenocarcinoma: 
impact on optimal treatment sequencing in second‑ 
and further treatment lines
Table 3 shows the responses for the 11 statements in this 
domain. A high degree of consensus (88–100%) was estab-
lished, confirming the overall acceptance that new first-line 
immunotherapy-based treatments in routine clinical practice 
will reduce its use in later lines. There was a shared concern 
for the resulting economic impact.
After progression to first-line platinum, pemetrexed, and 
pembrolizumab, the administration of docetaxel and nin-
tedanib may be the most appropriate therapeutic option. 
After progression to first-line carboplatin, paclitaxel, 
Table 1  General aspects of the current treatment of advanced wild-type lung adenocarcinoma
In bold, respondents attaining a consensus or a majority
Round 1: 1 = “Strongly disagree”; 2 = “Basically disagree”; 3 =  “Doubtful”; 4 =  “Basically agree”; 5 =  “Strongly agree”
Round 2: 1 =  “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Basically agree”; 4 =  “Strongly agree”
a Percent of respondents who chose a utility rating disagree (1 or 2) or agree (3 or 4)
Round Range of responses (N = 26) % of  panela Final consensus
1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
1. Currently, after recent positive first-line Phase 3 studies of immu-
notherapy alone or in combination with chemotherapy, there are 
uncertainties about which would be the best treatment sequence for 
patients with advanced lung adenocarcinoma who have progressed 
after receiving these new therapeutic strategies
1 3.8 3.8 11.5 38.5 42.3 Consensus
2 7.7 0 19.2 73.1 92.3
2. It is not feasible to repeat the Phase 3 studies of approved treat-
ments in a patient population that had previously received the 
newer front-line therapeutic strategies to obtain high-level “con-
ventional” scientific evidence
1 0 0 19.2 46.2 34.6 Unanimity
2 0 0 34.6 65.4 100
3. Under these circumstances, the opinion and clinical experience of 
experts managing patients with lung cancer are essential to define 
the best therapeutic strategy and/or sequence of treatments
1 0 7.7 23.1 38.5 30.8 Consensus
2 0 7.7 30.8 61.5 92.3
4. The absence of the aforementioned “conventional” scientific 
evidence should not hinder access to the best therapeutic sequence 
according to the criteria of lung cancer experts
1 3.8 7.7 15.4 50.0 23.1 Consensus
2 0 3.8 26.9 69.2 96.1
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bevacizumab, and atezolizumab, the combination of doc-
etaxel and nintedanib could be a therapeutic option. Single-
agent pemetrexed is also a reasonable therapeutic option as it 
has demonstrated efficacy in the second-line setting, but with 
a more favourable safety profile than docetaxel alone [33] 
and may be a preferred option for disease with low aggres-
siveness. In patients experiencing early disease progression 
to first-line treatment and/or a high symptomatic tumour 
load, the combination of docetaxel and nintedanib may be 
more appropriate. On the other hand, after progression to 
a first-line immunotherapy regimen without chemotherapy, 
the most appropriate second-line therapeutic option would 
be platinum-based chemotherapy.
Upon progression to second-line platinum-based chemo-
therapy after first-line immunotherapy, a third-line regimen 
should consider treatment with the combination of docetaxel 
and nintedanib, or single-agent docetaxel or pemetrexed. The 
following variables are important when selecting third-line 
treatment: previous treatments, aggressiveness of disease 
progression (early progression and a high symptomatic 
tumour load), and accumulated toxicity. Higher aggressive-
ness of the disease would favour the use of the docetaxel and 
nintedanib combination.
In this clinical context, there is no scientific evidence that 
the reintroduction of an immunotherapy-based treatment is 
effective, so it should be considered only in a clinical trial 
setting.
Treatment after platinum‑based chemotherapy 
without immunotherapy in advanced wild‑type 
lung adenocarcinoma: options and optimal 
therapeutic sequencing
Table 4 shows the responses for the 12 statements in this 
domain. A high degree of consensus was attained in 10 
of the 12 statements (88–100%). One statement required 
Table 2  Durvalumab as consolidation therapy after platinum-based chemoradiotherapy in Stage III wild-type lung adenocarcinoma: impact on 
subsequent treatment lines
In bold, respondents attaining a consensus or a majority
Round 1: 1 = “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Doubtful”; 4 =  “Basically agree”; 5 =  “Strongly agree”
Round 2: 1 =  “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Basically agree”; 4 =  “Strongly agree”
TMB tumour mutation burden
a Percent of respondents who chose a utility rating disagree (1 or 2) or agree (3 or 4)
Round Range of responses (N = 26) % of  panela Final consensus
1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
1. In patients with locally advanced lung adenocarcinoma treated 
with platinum-based chemoradiotherapy who progress during con-
solidation treatment with durvalumab, the progression-free interval 
may condition subsequent salvage treatment
1 0 3.8 23.1 30.8 42.3 Consensus
2 0 3.8 15.4 80.8 96.2
2. If the interval between the end of chemoradiotherapy and disease 
progression is less than 6 months, subsequent salvage therapy 
would be considered as a second line of treatment, so nintedanib 
and docetaxel could be a reasonable alternative
1 0 11.5 15.4 30.8 42.3 Consensus
2 3.8 7.7 15.4 73.1 88.5
3. If the interval between the end of chemoradiotherapy and disease 
progression is greater than 6 months but less than 12 months, it 
is reasonable to evaluate treatment with platinum-based chemo-
therapy, or docetaxel ± nintedanib, or pemetrexed depending on the 
interval itself (closer to 6 months vs. 12 months), the aggressive-
ness of the progression and accumulated toxicity
1 0 11.5 19.2 38.5 30.8 Consensus
2 7.7 7.7 23.1 61.5 84.6
4. If the interval between the end of chemoradiotherapy and disease 
progression is greater than 12 months, treatment with a platinum-
based chemotherapy could be a reasonable alternative
1 0 0 7.7 42.3 50.0 Consensus
2 0 3.8 19.2 76.9 96.1
5. In patients with locally advanced lung adenocarcinoma treated 
with platinum-based chemoradiotherapy who progress after com-
pleting treatment with durvalumab, treatment with platinum-based 
chemotherapy may be a reasonable alternative
1 0 0 19.2 34.6 46.2 Consensus
2 0 3.8 15.4 80.8 96.2
6. There is no evidence that the reintroduction of immunotherapy 
is effective, so it is reasonable to only offer it in the context of a 
clinical study. However, the following variables should be assessed 
when considering reintroducing immunotherapy: the time elapsed 
since the last cycle of durvalumab, tumour expression of PD-L1, 
and TMB
1 0 3.8 7.7 50.0 38.5 Consensus
2 0 11.5 19.2 69.2 88.4
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Table 3  First-line immunotherapy ± chemotherapy in advanced wild-type lung adenocarcinoma: impact on optimal treatment sequencing in sec-
ond- and further treatment lines
In bold, respondents attaining a consensus or a majority
Round 1: 1 = “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Doubtful”; 4 =  “Basically agree”; 5 =  “Strongly agree”
Round 2: 1 =  “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Basically agree”; 4 =  “Strongly agree”
NA not applicable
a Percent of respondents who chose a utility rating disagree (1 or 2) or agree (3 or 4 in the second Delphi round/4 or 5 in the first Delphi round)
Round Range of responses (N = 26) % of  panela Final consensus
1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
1. Given the positive results of KEYNOTE 024 (pembrolizumab in 
PD-L1 ≥ 50%), KEYNOTE 042 (pembrolizumab in PD-L1 ≥ 1%), 
KEYNOTE 189 (pembrolizumab and chemotherapy), IMpower 
150 (atezolizumab, bevacizumab and chemotherapy) and Check-
Mate 227 (nivolumab and ipilimumab in TMB ≥ 10 mut/MB) 
Phase 3 studies, we expect that the majority of patients with 
advanced lung adenocarcinoma will be treated with first-line 
immunotherapy ± chemotherapy
1 0 3.8 3.8 34.6 57.7 Consensus
2 3.8 0 3.8 92.3 96.1
2. In the near future, calculating the mutational load in individual 
patients using sequencing techniques (NGS) is likely to become 
routine, since its value as a predictive biomarker of efficacy for 
immunotherapy has been confirmed
1 7.7 7.7 19.2 34.6 30.8 Consensus
2 3.8 3.8 42.3 50.0 92.3
3. Considering the high percentage of patients who will be treated 
with first-line immunotherapy, the implementation of economic 
measures ensuring patients’ access to these drugs and sustainability 
of the healthcare system is essential
1 0 0 0 26.9 73.1 100 Consensus
2 NA NA NA NA
4. Due to the enormous increase in first-line immunotherapy use, its 
administration as second-line or later treatment lines is likely to be 
significantly reduced in the coming years
1 0 0 19.2 26.9 53.8 Unanimity
2 0 0 7.7 92.3 100
5. Upon progression with first-line combination of chemotherapy 
(platinum + pemetrexed) and pembrolizumab, docetaxel and nint-
edanib could be a recommended treatment option
1 0 3.8 3.8 38.5 53.8 Consensus
2 0 3.8 15.4 80.8 96.2
6. Upon progression with first-line combination of chemotherapy 
(carboplatin + paclitaxel), bevacizumab and atezolizumab, doc-
etaxel and nintedanib could be a recommended treatment option
1 0 11.5 30.8 23.1 34.6 Consensus
2 0 11.5 34.6 53.8 88.4
7. In patients treated with first-line immunotherapy without chemo-
therapy (pembrolizumab or nivolumab + ipilimumab), platinum-
based chemotherapy would be the first treatment option when 
disease progression occurs
1 0 0 3.8 34.6 61.5 Unanimity
2 0 0 19.2 80.8 100
8. Patients who have progressed both to first-line immunotherapy 
(pembrolizumab or nivolumab + ipilimumab) and second-line plat-
inum-based chemotherapy should consider a third-line of treatment 
with docetaxel and nintedanib, docetaxel alone, or pemetrexed alone
1 0 0 7.7 38.5 53.8 Consensus
2 3.8 3.8 23.1 69.2 92.3
9. If a patient is treated with first-line immunotherapy (pembrolizumab 
or nivolumab + ipilimumab) followed by platinum-based chemo-
therapy at progression, at the time of the second progression, the use 
of docetaxel and nintedanib could be considered. This administration 
of docetaxel and nintedanib would be considered second-line chemo-
therapy (according to the SmPC, the docetaxel and nintedanib com-
bination is approved “after first-line chemotherapy”) even though the 
patient will be receiving their third-line of treatment
1 0 3.8 7.7 46.2 42.3 Consensus
2 0 3.8 19.2 76.9 96.2
10. Upon progression to platinum-based chemotherapy, the more 
aggressive the disease progression (early progression and symp-
tomatic tumour burden), the more recommendable it is to use the 
combination of docetaxel and nintedanib rather than docetaxel or 
pemetrexed alone
1 3.8 3.8 19.2 34.6 38.5 Consensus
2 0 7.7 19.2 73.1 92.3
11. Upon progression to first-line immunotherapy (pembrolizumab 
or nivolumab + ipilimumab) followed by progression to second-line 
platinum-based chemotherapy, there currently is no evidence that 
reintroduction of immunotherapy is effective. It is reasonable to 
only offer immunotherapy in the clinical study setting
1 0 0 7.7 19.2 73.1 92.3 Consensus
2 NA NA NA NA
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reformulation, one statement had a majority in disagreement, 
and one statement was in dissent; reflecting the uncertainties 
of treating patients in this clinical scenario.
Statement 1 (“tumour PD-L1 expression is a funda-
mental criterion to help therapeutic decision making in a 
patient previously treated with first-line platinum-based 
Table 4  Treatment after platinum-based chemotherapy without immunotherapy in advanced wild-type lung adenocarcinoma: options and opti-
mal therapeutic sequencing
In bold, respondents attaining a consensus or a majority
Round 1: 1 = “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Doubtful”; 4 =  “Basically agree”; 5 =  “Strongly agree”
Round 2: 1 =  “Strongly disagree”; 2 =  “Basically disagree”; 3 =  “Basically agree”; 4 =  “Strongly agree”
NA not applicable
a Percent of respondents who chose a utility rating disagree (1 or 2) or agree (3 or 4)
Round Range of responses (N = 26) % of  panela Final consensus
1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
1. Tumour PD-L1 expression is a fundamental criterion to help thera-
peutic decision making in a patient previously treated with first-line 
platinum-based chemotherapy
1 0 23.1 23.1 30.8 23.1 Reformulated
2 NA NA NA NA
1′. Tumour PD-L1 expression is a criterion to help therapeutic deci-
sion making in a patient previously treated with first-line platinum-
based chemotherapy
1 NA NA NA NA NA Consensus
2 0 11.5 34.6 53.8 88.4
2. When selecting second-line treatment options following progres-
sion to first-line platinum-based chemotherapy, another criterion to 
consider is tumour aggressiveness
1 0 0 23.1 53.8 23.1 Unanimity
2 0 0 23.1 76.9 100
3. When selecting second-line treatment options following progres-
sion to first-line platinum-based chemotherapy, tumour PD-L1 
expression, tumour aggressiveness, and accumulated toxicity from 
previous treatments should be assessed
1 3.8 0 19.2 38.5 38.5 Unanimity
2 0 0 19.2 80.8 100
4. When selecting second-line treatment options following progression 
to first-line platinum-based chemotherapy, the aggressiveness of the 
tumour could favour choosing docetaxel and nintedanib if tumour 
PD-L1 expression is negative
1 3.8 3.8 11.5 38.5 42.3 Consensus
2 0 3.8 19.2 76.9 96.2
5. When selecting second-line treatment options following progression 
to first-line platinum-based chemotherapy, the aggressiveness of the 
tumour could favour choosing docetaxel and nintedanib if tumour 
PD-L1 expression is low
1 3.8 3.8 26.9 46.2 19.2 Consensus
2 0 3.8 42.3 53.8 96.2
6. In a patient with unknown tumour PD-L1 expression and slow 
progression to first-line platinum-based chemotherapy, second-line 
immunotherapy could be a reasonable therapeutic option
1 0 0 3.8 61.5 34.6 Unanimity
2 0 0 19.2 80.8 100
7. In a patient with negative tumour PD-L1 expression and slow 
progression to first-line platinum-based chemotherapy, second-line 
immunotherapy could be a reasonable therapeutic option
1 0 11.5 7.7 61.5 19.2 Unanimity
2 0 0 19.2 80.8 100
8. Upon progression to second-line immunotherapy, one could con-
sider administering docetaxel and nintedanib as third-line treatment 
(second-line chemotherapy)
1 0 0 7.7 46.2 46.2 Consensus
2 0 7.7 19.2 73.1 92.3
9. Upon progression to second-line chemotherapy (docetaxel and 
nintedanib, docetaxel alone or pemetrexed alone), one could 
consider administering immunotherapy as third-line treatment, but 
exclusively in patients with positive tumour PD-L1 expression
1 7.7 42.3 30.8 11.5 7.7 Majority disagreement
2 7.7 53.8 23.1 15.4 61.5
10. Upon progression to second-line chemotherapy (docetaxel and nin-
tedanib, docetaxel alone or pemetrexed alone), one could consider 
administering immunotherapy as third-line treatment, independently 
of the tumour PD-L1 expression
1 0 11.5 23.1 46.2 19.2 Consensus
2 0 11.5 38.5 50.0 88.4
11. When considering administering third-line immunotherapy treat-
ment, one should assess the aggressiveness of the disease progres-
sion to previous second-line chemotherapy as well as tumour PD-L1 
expression
1 3.8 0 23.1 53.8 19.2 Consensus
2 3.8 0 46.2 50.0 96.2
12. In a patient with negative tumour PD-L1 expression treated with 
first-line platinum-based chemotherapy plus bevacizumab attain-
ing a disease control greater than 18 months, one could consider 
administering a second-line anti-angiogenic therapy (docetaxel and 
nintedanib) because of the benefit from the previous anti-angiogenic 
therapy
1 7.7 23.1 38.5 23.1 7.7 Dissent
2 3.8 38.5 42.3 15.4 57.7
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chemotherapy”) obtained a high proportion of “doubtful” 
responses (23.1%) in the first Delphi round. The scientific 
committee considered that the word “fundamental” could 
lead to confusion, so it was eliminated in the second Delphi 
round, achieving consensus.
The following variables should be considered when 
deciding second-line treatment after a first-line chemother-
apy regimen: aggressiveness of disease progression (early 
progression and a high symptomatic tumour load), tumour 
PD-L1 expression, previous treatment, and accumulated tox-
icity from previous treatments.
In patients with aggressive disease progression with low 
or negative tumour PD-L1 expression, the combination of 
docetaxel and nintedanib could be a reasonable therapeutic 
option as a second-line treatment. On the other hand, sec-
ond-line immunotherapy could be a reasonable therapeutic 
alternative in patients with a negative or unknown tumour 
PD-L1 expression in patients with slow disease progression.
At the time of progression to second-line immunotherapy, 
the third-line combination of docetaxel and nintedanib can 
be considered. Similarly, after a progression to second-line 
chemotherapy, the administration of third-line immuno-
therapy should be evaluated considering the aggressiveness 
of the progression to previous chemotherapy and tumour 
PD-L1 expression.
Statement 9 (“upon progression to second-line chemo-
therapy [docetaxel and nintedanib, docetaxel alone, or pem-
etrexed alone], one could consider administering immuno-
therapy as third-line treatment, but exclusively in patients 
with positive tumour PD-L1 expression”) obtained a major-
ity in disagreement (61.5%). The point of disagreement was 
interpreted to be related to “exclusively patients with posi-
tive tumour PD-L1 expression”. If the disease progression to 
a second-line chemotherapy was not aggressive, the admin-
istration of third-line immunotherapy could be evaluated 
independently of tumour PD-L1 expression.
Statement 12 (“in a patient with negative tumour PD-L1 
expression treated with first-line platinum-based chemo-
therapy plus bevacizumab attaining a disease control greater 
than 18 months, one could consider administering a sec-
ond-line anti-angiogenic therapy [docetaxel and nintedanib] 
because of the benefit from the previous antiangiogenic”) 
obtained a dissent (42% disagree vs. 58% agree). Experts 
who frequently use a first-line combination of chemother-
apy with bevacizumab to achieve a prolonged PFS, espe-
cially when tumour PD-L1 expression is negative, prefer to 
continue treatment at the time of progression with an anti-
angiogenic with a different mechanism of action, such as 
the combination of docetaxel and nintedanib [34]. On the 
other hand, experts without extensive experience with beva-
cizumab value that when such a prolonged PFS is obtained 
with first-line chemotherapy, the most reasonable thera-
peutic option in the second-line setting is immunotherapy 
regardless of the negative tumour PD-L1 expression. The 
results from the LUME-Lung 1 study of docetaxel and nin-
tedanib in patients with advanced NSCLC support the effi-
cacy in all patients with adenocarcinoma; however, there is 
lower benefit in long-term progressors, particularly those 
patients who progressed at least 12 months after initiation 
of first-line therapy.
Discussion
The current Delphi study shows that a high degree of con-
sensus exists among experts on how standard first-line 
immunotherapy-based regimens may be affecting decisions 
regarding subsequent treatment of patients with advanced 
wild-type lung adenocarcinoma. This consensus docu-
ment complements the information in the European Soci-
ety of Medical Oncology (ESMO), Sociedad Española de 
Oncología Médica (SEOM), National Institute for Health 
and Care Excellence (NICE), and other guidelines [35–37], 
and aims to provide oncologists with a specific therapeutic 
decision process to optimize management of patients when 
their disease has progressed after receiving immunotherapy.
As the treatment of NSCLC further evolves, it is impor-
tant to note that the following relevant scientific informa-
tion was communicated after the second Delphi round took 
place:
1. The use of durvalumab as a consolidation therapy after 
platinum-based chemoradiotherapy was limited by the 
European Medicine Agency (EMA) to patients with 
tumours expressing PD-L1 ≥ 1%. This restriction is a 
cause for concern among experts as it is judged to be 
based on non-robust analysis [38].
2. In an updated analysis of CheckMate 227 trial, differ-
ences in OS between the nivolumab and ipilimumab arm 
and the chemotherapy arm were not statistically signifi-
cant in the subgroup of patients with TMB ≥ 10 mut/Mb, 
with a HR of 0.77 (95% CI 0.56–1.06) [39].
3. Two Phase 3 first-line studies of atezolizumab plus 
chemotherapy in non-squamous NSCLC reported 
improved PFS outcomes compared with the control arms 
[25, 26]. OS improved in one study [25], but not the 
other one, although not being yet fully mature [26].
After careful analysis of this new information, the scien-
tific committee agreed that, despite its relevance, it did not 
affect the consensus statements or the elaboration of this 
document.
Although this consensus document aims to help thera-
peutic decision making, it has several limitations. First, 
this Delphi project has been developed under the premise 
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of patients with advanced wild-type lung adenocarci-
noma with a good general condition (ECOG PS 0 and 1) 
and without medical contraindications. This may limit 
the potential applicability of the Delphi consensus to all 
patients with advanced wild-type lung adenocarcinoma. 
This consensus document has been generated due to the 
lack of scientific evidence and with the realistic assump-
tion that completed Phase 3 studies will not be repeated in 
a population that has received immunotherapy. We would 
encourage to use this document to help stimulate discus-
sion on future real-world studies that could be carried out 
to support or question the consensus statements.
Several studies have suggested that treatment with 
immunotherapy does not condition the efficacy of subse-
quent chemotherapy. On the contrary, these studies seem 
to suggest an increase in the efficacy of chemotherapy 
[40–44], particularly when combined with anti-angiogenic 
agents [45–47], when administered after treatment with 
immunotherapy. Synergistic activity in both preclinical 
[48, 49] and clinical models [21, 22, 25, 26] support a 
hypothesis of a possible chemosensitization after prior 
exposure to immunotherapy. The changes induced by prior 
immunotherapy, as well as the “prolonged tissue half-life” 
of immunotherapy agents [50], could increase the efficacy 
of chemotherapy. The efficacy of chemotherapy in this set-
ting, may be further increased when combined with an 
anti-angiogenic agent [51, 52].
There is little scientific evidence that rechallenging 
patients with immunotherapy-based treatment is effective 
[30–32]. Currently, immunotherapy rechallenge should be 
considered only in the setting of a clinical trial.
In summary, due to the lack of scientific evidence, a panel 
of experts has developed a consensus document via a Del-
phi process that can help therapeutic decision making for 
the optimal management of second-line treatment as well 
as subsequent treatment lines of patients with advanced 
wild-type lung adenocarcinoma. These decisions should 
carefully evaluate previous treatment(s) administered and 
the PFS obtained, aggressiveness of the disease progression 
(early progression and a high symptomatic tumour burden), 
accumulated toxicity, tumour PD-L1 expression, and TMB 
(Table 5). We hope that dedicated research efforts can gen-
erate missing real-world evidence to fill data gaps in the 
clinical frameworks covered in this consensus document.
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Table 5  Variables for informing treatment decisions in patients with wild-type lung adenocarcinoma
Variables Clinical scenarios





apy ± chemotherapy in advanced 
disease
After treatment with platinum-based 
chemotherapy without immunotherapy 
in advanced disease
Clinical aggressiveness of the progres-
sion
 High symptomatic tumour load × × ×
 Early progression × × ×
Previous treatment × ×
Accumulated toxicity from previous 
treatments
× × ×
Progression-free interval with immu-
notherapy
×
PD-L1 expression × ×
Tumour mutational burden ×
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